FFO
LUCD icon

Fortitude Family Office’s Lucid Diagnostics LUCD Stock Holding History

Fortitude Family Office’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-481
Closed -$486 – 2038
2025
Q3 		$486 Buy
+481
New +$525 ﹤0.01% 1818

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fortitude Family Office's LUCD Position: Q4 2025 in Review

Fortitude Family Office sold out of Lucid Diagnostics (LUCD) in Q4 2025, closing a stake of 481 shares — an estimated $486 sold.

Fortitude Family Office first reported a position in LUCD in Q3 2025 and held it in 1 quarter. The position peaked at $486 in Q3 2025. 89 funds tracked by Wall St. Rank hold LUCD as of Q4 2025.

  • Fortitude Family Office reported no remaining Lucid Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Fortitude Family Office sold 481 Lucid Diagnostics shares in Q4 2025, an estimated $486.
  • Fortitude Family Office first reported a position in Lucid Diagnostics in Q3 2025 and held it in 1 quarter.
  • Fortitude Family Office's Lucid Diagnostics position peaked at $486 in Q3 2025.
  • 89 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q4 2025.

Based on Fortitude Family Office's 13F filing for Q4 2025, filed 15 Jan 2026.